The study of the effect of cytapheresis against secondary failure of biologics therapy in inflammatory bowel disease maintenance therapy.

The study of the effect of cytapheresis against secondary failure of biologics therapy in inflammatory bowel disease maintenance therapy. - CAPBIO

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000028719

Enrollment

Registered

2017-09-01

Start date

2015-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis Crohn&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients who would combine CAP therapy among the patients in maintenance administration with antiTNF - alpha antibody preparation (infliximab (Remicade), adalimumab (Humira)) among ulcerative colitis, patients with Crohn's disease with whole outpatient department and hospitalizing.

Exclusion criteria

Exclusion criteria: The patients who had the infection that the report based on the infection method needs.

Design outcomes

Primary

Measure	Time frame
We judge combination therapy to have an effect with CRP, blood sedimentation, the improvement of the hemoglobin level by a blood test. Also, in a practice range, we conduct a colonoscope or small intestine endoscopy and determine the difference of the effect with the control group by improvement of the endoscopic score (Rutgeerts score, Mayo score).	—

Countries

Japan

Contacts

Public ContactHirotsugu Imaeda

Shiga University of Medical Science Division of Gastroenterology, Department of Medicine

imaeda@belle.shiga-med.ac.jp0775482217

Outcome results